Publications en collaboration avec des chercheurs de Hokkaido University Hospital (13)

2024

  1. At-admission prediction of mortality and pulmonary embolism in an international cohort of hospitalised patients with COVID-19 using statistical and machine learning methods

    Scientific Reports, Vol. 14, Núm. 1

  2. Damage measured by Damage Index for Antiphospholipid Syndrome (DIAPS) in antiphospholipid antibody-positive patients included in the APS ACTION registry

    Rheumatology (United Kingdom), Vol. 63, Núm. 3, pp. 772-779

  3. Thrombosis recurrence and major bleeding in non-anticoagulated thrombotic antiphospholipid syndrome patients: Prospective study from antiphospholipid syndrome alliance for clinical trials and international networking (APS ACTION) clinical database and repository (“Registry”)

    Seminars in Arthritis and Rheumatism, Vol. 65

2023

  1. Associations Among Antiphospholipid Antibody Types, Isotypes, and Titers: An AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Study

    Laboratory investigation; a journal of technical methods and pathology, Vol. 103, Núm. 6, pp. 100147

2022

  1. Characteristics of Patients With Antiphospholipid Antibody Positivity in the APS ACTION International Clinical Database and Repository

    Arthritis Care and Research, Vol. 74, Núm. 2, pp. 324-335

  2. ISARIC-COVID-19 dataset: A Prospective, Standardized, Global Dataset of Patients Hospitalized with COVID-19

    Scientific Data, Vol. 9, Núm. 1

2021

  1. Antiphospholipid antibody profile stability over time: Prospective results from the APS ACTION clinical database and repository

    Journal of Rheumatology, Vol. 48, Núm. 4, pp. 541-547

  2. Clinical and laboratory characteristics of Brazilian versus non-Brazilian primary antiphospholipid syndrome patients in AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) clinical database and repository

    Advances in Rheumatology, Vol. 61, Núm. 1

2020

  1. Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibody-positive patients from the APS ACTION Registry

    Lupus, Vol. 29, Núm. 11, pp. 1353-1363

2019

  1. Comparison of real world and core laboratory lupus anticoagulant results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) clinical database and repository

    Journal of Thrombosis and Haemostasis, Vol. 17, Núm. 12, pp. 2069-2080

  2. The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody–Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository

    Arthritis Care and Research, Vol. 71, Núm. 1, pp. 134-141

  3. The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort

    Seminars in Arthritis and Rheumatism, Vol. 49, Núm. 3, pp. 464-468

  4. The comparison of real world and core laboratory antiphospholipid antibody ELISA results from antiphospholipid syndrome alliance for clinical trials & international networking (APS ACTION) clinical database and repository analysis

    Thrombosis Research, Vol. 175, pp. 32-36